Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
    • Pipeline overview
    • DNV3837
    • DASMA
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events
    • Media
  1. Home
  2. Investors

Press releases

22.03.2010

Deinobiotics' project labelled

Deinobiotics, project led by Deinove in partnership with biotech company Nosopharm and two expert laboratories, CPBS (CNRS - University of...
19.02.2010

Biofuels specialist Deinove appoints Paul-Joël Derian, VP R&D at Rhodia to its Board of Directors

05.02.2010

Deinove has been selected to present at CleanEquity 2010

05.11.2009

Biofuels technology company Deinove receives €6m Oseo grant

15.10.2008

DEINOVE installs its laboratories in Montpellier, France

18.02.2008

Jacques Biton named CEO of Deinove

  • « first
  • ‹ previous
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23

Investors

  • Corporate governance
    • Board of Directors
    • Executive Committee
  • DEINOVE Shares
  • Financial Calendar
  • Documentation Center
    • Financial Reports
    • Investors slide deck
    • Analyst Coverage
    • Number of Shares and Voting Rights
    • Newsletter to Shareholders
    • Shareholders' Meetings
    • Declaration of transactions performed on company securities
    • Liquidity Agreement
    • Public offerings - Documentation
    • Bonds Convertible into Shares (OCA)
  • Press releases
  • Investor relations
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

    

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home